A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Conditions: Type 2 Diabetes Interventions: Drug: Orforglipron; Drug: Placebo Sponsors: Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Insulin | Lantus | Metformin | Research | Study